High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
ImmunityBio (NASDAQ:IBRX) shares climbed 7. 5% on Thursday after the company announced that the United Arab Emirates had granted marketing approval for ANKTIVA in two cancer indications, further expanding the therapy’s international regulatory reach.
Weekend chatter focused on ImmunityBio’s quiet July, with some bulls calling the silence the “quiet before the kraken.”
ImmunityBio (IBRX) is back in focus after its stock surged 282.7% year to date, as investors weigh speculation around Anktiva’s role in bladder cancer treatment alongside ongoing regulatory and valuation questions. See our latest analysis for ImmunityBio. Recent trading shows that momentum in ImmunityBio’s share price has cooled in the near term, with a 7 day share price return down 12.16%, following a year to date share price return of 282.67% and a 1 year total shareholder return of...
Traders remain focused on Anktiva’s potential label expansion for papillary bladder cancer, with an FDA decision date set for Jan. 6, 2027.
Saudi Arabia is key to the bull case after ImmunityBio launched Anktiva there for certain patients with bladder and lung cancer.
ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
XBI, which includes both SLS and IBRX, is on track for its strongest monthly performance since December 2023.
ImmunityBio, Inc. (NASDAQ:IBRX) was among the stocks on which Jim Cramer commented, as he emphasized that SpaceX investors are betting on Elon Musk rather than the company’s earnings. When a caller mentioned that, as per their observation, the company seems to have become a “mid-cap commercial revenue generator” from a “small-cap spec play,” Cramer remarked: […]
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the 10 Best Performing Growth Stocks So Far in 2026. On June 1, ImmunityBio, Inc. (NASDAQ:IBRX) reported that it presented two research posters and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, which was held from May 29 to June 2, 2026, in Chicago. […]
Over the last 7 days, the United States market has dropped by 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this context of fluctuating performance and anticipated growth, stocks with high insider ownership can be appealing as they often signal confidence from those closest to the company's operations and potential for substantial earnings growth.
ImmunityBio (NasdaqGS:IBRX) presented new clinical data on ANKTIVA in advanced non small cell lung cancer and BCG unresponsive non muscle invasive bladder cancer at the 2026 ASCO Annual Meeting. The update included the first substantial ANKTIVA data readout in non small cell lung cancer and new comparative data in non muscle invasive bladder cancer. These ASCO presentations expand the clinical picture for ANKTIVA across major solid tumor types beyond bladder cancer. For investors following...
ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.
IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.
ImmunityBio Inc. (NASDAQ:IBRX) is one of the best mid cap stocks to buy with highest upside potential. On May 22, ImmunityBio recently presented a health economic analysis at ISPOR 2026 demonstrating that ANKTIVA combined with BCG provides superior economic value compared to TAR-200 for patients with BCG-unresponsive non-muscle-invasive bladder cancer/NMIBC. Using a cost-consequence model based […]
In May 2026, ImmunityBio reported that the FDA accepted for review its supplemental Biologics License Application for ANKTIVA plus BCG to treat BCG-unresponsive non-muscle invasive bladder cancer with papillary disease, setting a PDUFA action date of January 6, 2027. The filing leans heavily on QUILT 3.032 data and an FDA-indicated focus on extrapolating results from CIS patients, which could materially broaden ANKTIVA’s approved bladder cancer population if the agency agrees. We’ll now...
ImmunityBio presented its findings for ANKTIVA plus Bacillus Calmette-Guérin at the ISPOR 2026 conference.
ImmunityBio (IBRX) has been drawing attention after its lead product candidate Anktiva received FDA approval for use with BCG in certain bladder cancer patients, prompting investors to reassess the company’s broader immunotherapy pipeline and valuation. See our latest analysis for ImmunityBio. Since the FDA approval, ImmunityBio’s share price has cooled in the very short term, with 1-day and 7-day share price returns down 3% and 4.43%. However, the year-to-date share price return of 284.16%...
ImmunityBio's shares rise after the FDA accepts a filing to expand Anktiva's use in bladder cancer, with a decision due by January 2027.
IBRX secures five U.S. patents for Anktiva in bladder cancer, extending franchise protection through 2035 amid strong sales growth.
Stock Moves Higher Following Patent AnnouncementShares of ImmunityBio (NASDAQ:IBRX) gained 4. 5% in premarket trading on Monday after the company announced the issuance of five U.
Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...
The United States market remained flat over the last week, yet it has experienced a significant 28% rise over the past 12 months with earnings projected to grow by 16% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best.
IBRX's Q1 outlook rides on Anktiva's surging uptake, with preliminary revenues showing triple-digit growth ahead of its earnings report later this month.
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 9, ImmunityBio, Inc. (NASDAQ:IBRX) delivered impressive preliminary operational results for its fiscal quarter ending March 31, 2026. Product revenue in the quarter was up 168% year over year to $44.2 million. The increase […]
ImmunityBio has now commercially launched its immunotherapy ANKTIVA in Saudi Arabia for approved bladder and metastatic non-small cell lung cancer indications, with distribution supported by regional partners Biopharma and Cigalah Healthcare and its local subsidiary. This marks one of the first commercial rollouts of ANKTIVA for both bladder and lung cancer in the Middle East and North Africa, a region facing a rapidly growing cancer burden and rising demand for additional treatment...
We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. ImmunityBio, Inc. is one of the best biotech stocks on our list. TheFly reported on April 21 that ImmunityBio, Inc. (NASDAQ:IBRX) announced that its immunotherapy ANKTIVA has begun commercial availability in Saudi Arabia, with initial patients already identified for treatment. […]
ImmunityBio, Inc. (NASDAQ:IBRX) was among Jim Cramer’s recent stock calls on Mad Money. Answering a caller’s query about the stock during the recent lightning round, Cramer said: You know there’s a lot of dispute about what they did. And I’m going to tell you that it is not clear exactly what they did wrong, but […]
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.